New human CD22/siglec-2 ligands with a triazole glycoside
CD22 is a member of the Siglec family. Considerable attention has been drawn to the design and synthesis of new Siglec ligands to explore target biology and innovative therapies. In particular, CD22-ligand-targeted nanoparticles with therapeutic functions have proved successful in preclinical settin...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
04 April 2017
|
| In: |
ChemBioChem
Year: 2017, Volume: 18, Issue: 13, Pages: 1216-1225 |
| ISSN: | 1439-7633 |
| DOI: | 10.1002/cbic.201600707 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1002/cbic.201600707 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/cbic.201600707 
|
| Author Notes: | Horst Prescher, Astrid Schweizer, Elena Kuhfeldt, Lars Nitschke, and Reinhard Brossmer |
| Summary: | CD22 is a member of the Siglec family. Considerable attention has been drawn to the design and synthesis of new Siglec ligands to explore target biology and innovative therapies. In particular, CD22-ligand-targeted nanoparticles with therapeutic functions have proved successful in preclinical settings for blood cancers, autoimmune diseases, and tolerance induction. Here we report the design, synthesis and affinity evaluation of a new class of Siglec ligands: namely sialic acid derivatives with a triazole moiety replacing the natural glycoside oxygen atom. In addition, we describe important and surprising differences in binding to CD22 expressed at the cell surface for compounds with distinct valences. The new class of compounds might serve as a template for the design of ligands for other members of the Siglec family and next-generation CD22-ligand-based targeted therapies. |
|---|---|
| Item Description: | Gesehen am 24.09.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1439-7633 |
| DOI: | 10.1002/cbic.201600707 |